10-Q · May 12, 2026
Unicycive reported a significant miss in Q4 2025 earnings with an EPS of -$0.82 against estimates of -$0.46 and showed no revenue, ignored consensus targeting a revenue of $590,860. The quarter's loss from operations…
Earnings analysis · 10-Q
UNCY earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement or segment disclosures, so current-period revenue, margins, EPS, cash burn and free cash flow cannot be quantified.…
Read full summary
The provided 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement or segment disclosures, so current-period revenue, margins, EPS, cash burn and free cash flow cannot be quantified. Disclosure controls were deemed effective as of June 30, 2026, with no material internal-control changes during the six months ended June 30, 2026. The main developments are significant unresolved litigation—including a securities class action filed on August 15, 2025—and a newly added risk concerning strategic transactions that could dilute shareholders and reduce operating resources.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure Controls Remained Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information was recorded and reported timely.
-
No Material Control Changes
The company reported no changes during the six months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
Derivative Actions Stayed
The court entered an order on July 29, 2026 staying the derivative actions pending resolution of the motion to dismiss in the securities class action, potentially limiting near-term derivative-litigation activity.
What to watch
-
Strategic Transactions Could Dilute Cash
The company disclosed a new risk concerning potential strategic transactions, including acquisitions that could require debt or equity issuance, dilute existing stockholders, divert management attention, increase expenses and reduce cash available for operations.
-
Securities Litigation Remains Uncertain
The securities class action alleges misrepresentations related to OLC manufacturing and NDA approval prospects; defendants filed a motion to dismiss on March 13, 2026, but the company stated it cannot predict the outcome or estimate potential losses.
-
Derivative Litigation Could Be Material
Two derivative complaints were consolidated on April 30, 2026 and seek unspecified damages, governance reforms, disgorgement and restitution; the company warned that defense costs could be material even if it prevails.
Management's outlook
The provided filing text contains no quantitative revenue or EPS outlook. No change in prior outlook can be determined from the available disclosure.
Earlier filings 4
10-K · March 30, 2026
Unicycive is a clinical-stage renal-focused biotech with two programs (oxylanthanum carbonate and UNI-494). The company has generated no product revenue to date and continues to report negative EPS and negative free…
10-Q · August 14, 2025
Unicycive reported no revenue and a net loss per share of $(0.52) for the quarter ended June 30, 2025, driven by operating loss of $(6,963) and continuing fair value volatility in its warrant liability. Cash and cash…
10-Q · November 13, 2024
Unicycive (UNCY) reported no revenue for the three months ended September 30, 2024 and a net loss of $(4,096) (versus $(4,333) in the prior-year quarter), producing EPS of $(0.05) compared with $(0.13) a year earlier.…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.